| Ytd | 3.71% | |
| 1y | 3.32% |
| Open | 10.89 | Prev Close | 10.89 | Low | 10.89 | High | 10.89 | Mkt Cap | 54.54M |
| Vol | 272.00 | Avg Vol | 2.43K | EPS | -0.17 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | 0.35 | Inst. Own | 72.44% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 10.81 | 200-d Avg | 10.69 | 1yr Est | 0.00 |
Charles River Laboratories International (NYSE: CRL - Get Free Report) and IB Acquisition (NASDAQ: I
BOCA RATON, FL AND TORONTO, ONTARIO, March 16, 2026 (GLOBE NEWSWIRE) -- GNQ Insilico Inc. (“GNQ” or
Crossingbridge Advisors LLC boosted its stake in shares of IB Acquisition Corp. (NASDAQ: IBAC) by 10
DLD Asset Management LP bought a new stake in IB Acquisition Corp. (NASDAQ: IBAC) during the third q
Shares of IB Acquisition Corp. (NASDAQ: IBAC - Get Free Report) dropped 0.2% on Tuesday. The stock t
IB Acquisition Corp. (NASDAQ: IBAC - Get Free Report) shot up 0.1% during mid-day trading on Monday.
IB Acquisition Corp priced its initial public offering of 10,000,000 units at a price to the public